## 2 Materials and Methods
### Psychometric and Clinical Assessments  
QoL was assessed with the Dermatology Life Quality Index (DLQI), which contains ten questions covering different topics related to skin disease such as symptoms, change in habits, hobies, clothing style, leisure and social activities [12; 13; 14]. Because of its simplicity and reliable grading, DLQI is widely used in numerous clinical and non-clinical studies. The minimum and the maximum scores vary between 0 and 30, and the higher the score the higher the QoL impairment. Sleeping problems were evaluated using 3 simple questions about problems in falling asleep, frequent awakenings and using sleeping medication. The \(11\)-point Numerical Rating Scale ranging from 0 (no pruritus) to 10 (worst imaginable pruritus) was used to assess the maximal (NRSmax) and average (NRSaverage) intensity of pruritus during the last three days [15]. The other method of pruritus intensity measurement was the 10-item Pruritus Severity Scale (10-PSS) [16]. In this scale, questions about the severity of pruritus (two questions), duration of itch episodes (one question), localization of pruritus (one question), influence on patient's concentration and psyche (four questions), and scratching behaviors in response to itching (two questions) were included. 10-PSS scoring ranges from 3 to 20 with a higher score indicating more intense pruritus. \begin{table}
\begin{tabular}{c c c c c c c} \hline \hline  & **Number of Subjects (\%)** & **Gender** & **Age** & **BMI** & **Age at Disease** & **Coexisting Psoriatic** \\  & **Subjects (\%)** & **Female (\%)** & **Min–Max** & **Min–Max** & **Mean \(\pm\) SD** & **Mean \(\pm\) SD** & **Mean \(\pm\) SD** \\ \hline
**All subjects** & 295 (100) & 148 (50.2)/ & 16–77 & 14.5–46.0 & 2–76 & 27 (9.2) \\  & & 147 (49.8) & (45.0 \(\pm\) 15.3) & (27.5 \(\pm\) 5.6) & (32.9 \(\pm\) 16.8) & \\ \hline
**Large plaque** & 45 (15.3) & 15 (33.3) & 17–77 & 21.4–42.8 & 6–72 & \\
**posoriasis** & & 30 (66.7) & (46.7 \(\pm\) 15.9) & \(p\) \(<\) 0.001 \({}^{*}\) & (30.3 \(\pm\) 17.5) & 5 (11.1) \\ \hline
**Small plaque** & 32 (10.8) & 11 (34,4) & 16–69 & 14.5–37.6 & 3–58 & \\
**posoriasis** & & 21 (65.6) & (40.6 \(\pm\) 13.6) & (26.4 \(\pm\) 5.3) & (27.3 \(\pm\) 15.1) & 2 (6.3) \\ \hline
**Gutate** & 31 (10.5) & 14 (45.2) & 17–73 & 19.5–46.0 & 7–53 & \\
**posoriasis** & & 17 (54.8) & (37.5 \(\pm\) 11.6) & (27.5 \(\pm\) 6.4) & (24.0 \(\pm\) 12.1) & 4 (12.9) \\ \hline
**Palmoplantar** & 33 (11.2) & 18 (54.6) & 16–71 & 18.1–43.4 & 10–69 & \\  & & 15 (45.4) & (45.3 \(\pm\) 14.9) & (28.3 \(\pm\) 5.7) & (36.1 \(\pm\) 16.5) & 2 (6.1) \\ \hline
**Scalp psoriasis** & 32 (10.8) & 19 (59.4) & 16–61 & 15.4–34.1 & 6–50 & \\  & & 13 (40.6) & (34.9 \(\pm\) 12.4) & \(p\) \(<\) 0.001 \({}^{*}\) & (23.7 \(\pm\) 11.7) & 2 (6.3) \\ \hline
**Inverse** & 23 (7.8) & 12 (52.2) & 18–67 & 18.8–41.5 & 13–60 & \\
**posoriasis** & & 11 (47.8) & (41.5 \(\pm\) 14.0) & (29.3 \(\pm\) 5.6) & (30.7 \(\pm\) 14.2) & 2 (8.7) \\ \hline
**Erythrodermic** & 33 (11.2) & 9 (27.3) & 18–71 & 17.6–44.5 & 3–60 & \\
**posoriasis** & & 24 (72.7) & (47.5 \(\pm\) 16.6) & (27.8 \(\pm\) 6.4) & (31.9 \(\pm\) 16.7) & 5 (15.2) \\ \hline
**Palmoplantar** & & 37 (86.1) & 28–77 & 18.8–37.2 & 16–69 & \\
**pustular** & 43 (14.6) & 6 (13.9) & (53.8 \(\pm\) 12.6) & (26.4 \(\pm\) 4.5) & (45.7 \(\pm\) 12.1) & 1 (2.3) \\
**posoriasis** & & & \(p\) \(<\) 0.001 \({}^{*}\) & & \(p\) \(<\) 0.001 \({}^{*}\) & \\ \hline
**Generalized** & & & & & & \\
**pustular** & 23 (7.8) & 13 (56.5) & (54.9 \(\pm\) 14.3) & 17.2–39.3 & 2–76 & \\
**posoriasis** & & 10 (43.5) & (5.0 \(\pm\) 0.001 \({}^{*}\) & (27.0 \(\pm\) 4.8) & (45.5 \(\pm\) 19.1) & 4 (17.4) \\ \hline \hline \end{tabular}
\end{table} 
Table 1: Comparison of demographic, anthropometric and clinical data in patients with various clinical subtypes of psoriasis (statistically significant differences from other patients (\(p<\) 0.05) were marked with \({}^{**}\)).